I rate Reckitt Benckiser a buy with a 12–24 month horizon and medium confidence, citing a 21% discount to peer multiples despite litigation overhang. Core Reckitt delivers high-margin, volume-led growth, with FY2025 organic growth of +5.2% and a 26.7% adjusted operating margin, supporting quality business status. Mead Johnson litigation risk remains the key discount driver; recent favorable legal outcomes improve sentiment but do not resolve federal MDL exposure.
Reckitt delivered solid H1 results, with top line growth in both Core Reckitt and Mead Johnson Nutrition, despite regional disparities. RBGLY's operating profit, margin, and cash flow fell, mainly due to the Essential Home divestment, but management remains confident about forward momentum. The interim dividend grew 5% to 88.6p, yielding 4.2%, and a new £500m buyback was announced, signaling ongoing capital returns.
Reckitt Benckiser Group LON: RKT reported accelerating sales growth in the second quarter of 2026, supported by innovation, emerging-market demand and a return to growth in North America, while maintaining its full-year outlook despite commodity and supply-chain volatility.
The Lysol, Mucinex and Durex-condom maker issued a new share buyback program after reporting 4.7% like-for-like net revenue, bolstered by growth in emerging markets.
The deal with Russia's Arnest Management—which manufactures cosmetics and household goods—is expected to complete during the second half of 2026.
Jefferies has upgraded Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, XETRA:3RB)to 'buy' from 'hold', raising its price target to 5,900p from 5,600p ahead of half-year results next week. The broker argues the market has overly discounted a run of setbacks that hit the consumer goods group in early 2026, most of which it classes as one-off and unlikely to recur beyond this year.
Reckitt Benckiser is experiencing a market overreaction to the downside, creating an attractive entry point below £46/share. RBGLY's recent share price decline is driven by temporary macro headwinds—oil price sensitivity and a weak cold/flu season—not by fundamental business weakness. I have rebased my valuation to a 15x P/E multiple, lowering my price target to £46/share, and now rate the stock a 'Buy.'
Reckitt Benckiser Group LON: RKT executives used an investor “Focus On” event to outline how the company is applying digital science, artificial intelligence and predictive modeling across its innovation process, saying the capabilities are intended to support faster product development, stronger launch execution and efficiency gains.
Reckitt Benckiser Group plc (RBGLY) Q1 2026 Sales/Trading Call Transcript
Reckitt stock fell about 5% in early trading on Wednesday after the consumer goods group said first-quarter core like-for-like net revenue rose only 1.3%. The figure was well below the 2.9% analysts had expected, and warned that first-half adjusted operating margin would be roughly 200 basis points lower than a year earlier.
Lysol maker Reckitt Benckiser booked a rise in first-quarter like for like revenue, helped by strong emerging markets performance, where like-for-like sales grew 7.6%.
RBGLY, SOUHY and SUNS have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2026.